New EU Regulation Addresses Many, But Not All, Of Medtech’s Procurement Concerns
MedTech Europe welcomes plans for value-based procurement, but argues that more definitive rules are needed.
Medtech Insight - September 24, 2026

Formycon Points To Benefits For Early Movers On Biosimilar Streamlining
Formycon has set out its belief that an early decision to terminate Phase III trials for its FYB206 proposed biosimilar to Keytruda (pembrolizumab) has played a “pioneering” role in demonstrating the benefits to developers of regulatory streamlining.
Generics Bulletin - September 24, 2026

Execs On The Move: September 14–18, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - September 24, 2026

Novartis Wins Entresto Antitrust Fight Over Six-Month Generic Delay
A New York federal court has dismissed an Entresto antitrust suit, finding Novartis properly listed the disputed ’659 patent in the Orange Book despite arguments that it did not specifically claim the drug’s valsartan-sacubitril complex.
Generics Bulletin - September 24, 2026

Publisher’s Spotlight: Scrip Awards Announces 2026 Finalists
We are delighted to announce the shortlist for the Annual Scrip Awards. Now in their 22nd year, the Awards seek to reward the outstanding achievements of the pharmaceutical, biotech and allied industries in improving human health.
Scrip - September 24, 2026

Lilly Adds Another China Partner With InnoCare $100m Upfront Deal
The pharma giant continues its China partnering spree with a deal to discover and develop up to five therapies in cancer and autoimmune diseases.
Scrip - September 24, 2026

EFSA Issues First Positive CBD Opinion – At A Fifth Of The UK Dose
EFSA has cleared its first CBD novel food, a synthetic ingredient from Chanelle McCoy, but at just 2mg a day for over-25s. That is a fifth of the dose the UK's food regulator board has just backed for a similar products from the same manufacturer.
HBW Insight - September 24, 2026

Kasvu All Set To Advance New Class In Depression
The Finnish biotech has banked €30m to take its non-hallucinogenic TrkB potentiator into the clinic.
Scrip - September 24, 2026

‘We Will Remain Relentless In Our Focus’ – Sandoz CCO Guntern On The Firm’s ‘Pure Play’ Ambitions
Speaking to Generics Bulletin after Sandoz unveiled its Bio 100 long-term strategy, chief commercial officer Rebecca Guntern discusses the significance of both small-molecule generics and biosimilars for the company, while also touching on aspects such as GLP-1s, US tariffs and M&A opportunities.
Generics Bulletin - September 24, 2026

FDA Panel Backs GRAIL’s Multi-Cancer Test, But Split Votes Put ‘Early Detection’ Claim In Play
The panel voted unanimously on safety but split 6-4 on effectiveness, and urged the agency to rein in “early” claims – a labeling fight that could set the bar for rival MCEDs and shape Medicare coverage from 2028.
Medtech Insight - September 24, 2026

Telling A Growth Story: What Makes, And Breaks, A Consumer Health Divestment
Senior M&A advisors explore the factors driving premium outcomes for consumer health divestitures, including rigorous carve-out preparation, selling from strength and competitive buyer tension. Part three of HBW' Insight's 'Inside Consumer Health M&A' series.
HBW Insight - September 24, 2026

Simcere Envisions World-Facing R&D To Scale Up Global Partnerships
Simcere president Yunshu Zhou pinpoints Chinese firm’s next steps in deal making, based on a renewed R&D rationale in a global context.
Scrip - September 24, 2026

Ondine’s Steriwave: Will New Antimicrobial Development Finally Be Rewarded With Commercial Success?
Ondine Biomedical has now published phase III topline data for Steriwave, its drug-device hybrid technology capable of vastly reducing rates of surgical site infections.
In Vivo - September 24, 2026

Supplements Exempt From ‘Use By’ Labeling In California As New York Considers Requirement
California law which took effect in July included supplements as food products required to “use by” or “best used by” on labeling but requirement was lifted effective Sept. 18. New York lawmakers advanced similar requirement before legislative session ended in June.
HBW Insight - September 24, 2026

Sunscreen Preservative Problem Has Answer: Multifunctional Glycols – Manufacturer
As traditional preservatives face mounting consumer and regulatory pressure, sunscreen formulators are turning to glycol-based multifunctionals that protect, improve texture, boost SPF, and score well with ingredient-scrutiny apps.
HBW Insight - September 24, 2026